Acyclovir in the treatment of hand-foot-and-mouth disease

Cutis. 1996 Apr;57(4):232-4.

Abstract

Twelve children ages 1 to 5 years and one adult with hand-foot-and-mouth disease were treated with oral acyclovir within one to two days of onset of the rash. Symptomatic relief, defervescence, and significant involution of lesions were seen within twenty-four hours of initiating therapy. Acyclovir was continued for five days, by which time palmar, plantar, and oral lesions were virtually gone. Acyclovir is a molecule tailored to inactivate the thymidine kinase of the herpesvirus. Since the Coxsackie A16 virus causing hand-foot-and-mouth disease lacks this enzyme, the beneficial therapeutic effect must be explained on other grounds, possibly due to enhancement of the antiviral effect of the patient's own interferon.

Publication types

  • Clinical Trial

MeSH terms

  • Acyclovir / administration & dosage
  • Acyclovir / therapeutic use*
  • Administration, Oral
  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Child, Preschool
  • Drug Administration Schedule
  • Female
  • Hand, Foot and Mouth Disease / diagnosis
  • Hand, Foot and Mouth Disease / drug therapy*
  • Humans
  • Infant
  • Male
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Acyclovir